finbosertib   Click here for help

GtoPdb Ligand ID: 14612

Synonyms: compouind 19 [WO2022069509]
Compound class: Synthetic organic
Comment: Finbosertib is the INN for a serine/threonine kinase inhibitor (WHO INN Proposed List 135; July 2026). The same chemical structure is claimed as a transforming growth factor-β receptor I (ALK5) inhibitor in patent WO2022069509A1 (Origo Biopharma), that is proposed for the treatment of respiratory diseases [1]. Agomab acquired Origo in 2021. Finbosertib is likely to be the INN for Agomab's lung-restricted lead ALK5 inhibitor ORG-447.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 10
Hydrogen bond donors 2
Rotatable bonds 11
Topological polar surface area 110.99
Molecular weight 593.65
XLogP 0.61
No. Lipinski's rules broken 1

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

SMILES / InChI / InChIKey
Click here for help
Canonical SMILES CC1=CC=CC(=N1)C2=NN(C=C2C3=C4C=CC=CC4=NC=C3)CC(=O)NC5=CC(=CC(=C5)C(=O)OCCN6CCNCC6)F
Isomeric SMILES CC1=NC(=CC=C1)C2=NN(C=C2C3=CC=NC4=CC=CC=C34)CC(=O)NC5=CC(=CC(=C5)C(=O)OCCN6CCNCC6)F
InChI InChI=1S/C33H32FN7O3/c1-22-5-4-8-30(37-22)32-28(26-9-10-36-29-7-3-2-6-27(26)29)20-41(39-32)21-31(42)38-25-18-23(17-24(34)19-25)33(43)44-16-15-40-13-11-35-12-14-40/h2-10,17-20,35H,11-16,21H2,1H3,(H,38,42)
InChI Key IULPVLPJSYRUDQ-UHFFFAOYSA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

References
1. Artal RB, Casal BP, Laria JCP. (2022)
2-(3-pyridin-2-yl-4-quinolin-4-yl-pyrazol-1-yl)-acetamide derivatives as inhibitors of transforming growth factor-beta receptor i/alk5.
Patent number: WO2022069509A1. Assignee: Origo Biopharma SL. Priority date: 29/09/2021. Publication date: 07/04/2022.